Testosterone Enanthate vs AndroGel: Cost, Access, and Clinical Comparison

Why This Comparison Matters for TRT Patients

Testosterone replacement therapy (TRT) is a long-term commitment. Most men diagnosed with hypogonadism will use exogenous testosterone for years, sometimes decades. That makes monthly cost, pharmacy access, and insurance formulary placement just as important as pharmacokinetics.

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic testosterone deficiency confirmed by at least two morning serum total testosterone measurements below 300 ng/dL [2]. The guideline does not prefer one formulation over another. It lists intramuscular injections, transdermal gels, transdermal patches, nasal gel, and subcutaneous pellets as acceptable options, leaving the decision to shared clinical judgment. That flexibility means cost and convenience often tip the scale.

Testosterone enanthate, available as a generic intramuscular injection since the 1950s, remains the least expensive testosterone formulation in the United States. AndroGel, approved by the FDA in 2000 as a 1% topical gel (later reformulated to 1.62%), became the most prescribed branded testosterone product before its patent expired. Generic testosterone gel 1% entered the market in 2015 and brought gel prices down, but not to injectable levels.

The price gap between these two routes of administration is not trivial. Over five years of therapy, a man paying cash could spend under $3,600 on enanthate injections or over $36,000 on brand AndroGel. That 10x difference makes the injectable the default choice for uninsured and underinsured patients.

Cost Breakdown: Cash Price, Insurance, and Copays

A 10 mL vial of testosterone enanthate 200 mg/mL, the standard generic product, costs $30 to $60 at most retail pharmacies using a GoodRx-type discount card. A typical dose of 100 mg weekly means one vial lasts roughly 10 weeks. Annual cash cost: approximately $150 to $350.

Brand AndroGel 1.62% in the 75-pump-metered-dose bottle (carrying a 30-day supply at two pumps daily) lists at $550 to $740 depending on pharmacy. Annual cash cost: $6,600 to $8,880. Even generic testosterone gel 1% in packets runs $80 to $150 monthly, putting the annual range at $960 to $1,800.

Insurance changes the math, but not always enough. Most commercial plans place generic testosterone enanthate on Tier 1 or Tier 2 with copays of $5 to $25. AndroGel brand often sits on Tier 3 (preferred brand) or non-formulary, triggering copays of $50 to $100 or requiring step therapy through a generic gel first. Some plans demand prior authorization for any branded testosterone product.

Medicare Part D formularies almost universally cover generic enanthate with minimal cost-sharing. Coverage for AndroGel brand varies by plan, and many Part D plans exclude it entirely or impose quantity limits [3]. The Centers for Medicare & Medicaid Services (CMS) does not classify testosterone as a protected class drug, giving plans wide latitude to restrict brand coverage.

For men with high-deductible health plans (HDHPs), the effective cost of AndroGel before meeting the deductible is full retail price. Testosterone enanthate, priced below most deductible thresholds on a per-fill basis, causes less financial strain during the deductible accumulation period. A man with a $3,000 deductible using brand AndroGel could exhaust the deductible on testosterone alone in four to five months.

Pharmacy Access and Supply Chain

Testosterone enanthate is manufactured by multiple generic companies including Perrigo, Hikma, and Sun Pharma. Virtually every retail pharmacy in the U.S. stocks it or can order it within 24 hours. Specialty pharmacy access is not required. The product ships at room temperature and has a shelf life of 36 months.

AndroGel brand is manufactured by AbbVie. While widely distributed, it is a controlled substance (Schedule III) like all testosterone products, and some pharmacies limit on-hand inventory of gels due to theft risk and shelf-space constraints. Generic testosterone gel is more reliably stocked, but patients occasionally report supply disruptions at smaller independent pharmacies.

Both formulations require a prescription. Federal law classifies all anabolic steroids, including testosterone, as Schedule III controlled substances under the Anabolic Steroids Control Act of 1990 [4]. Most states allow 90-day supplies, and mail-order pharmacy is permitted for both products. Telehealth prescribing of testosterone is legal in all 50 states as of 2026, though some states require an initial in-person visit before ongoing telehealth refills.

One access advantage of injections: patients can self-administer at home with proper training. The Endocrine Society guideline notes that intramuscular and subcutaneous self-injection are both acceptable [2]. This eliminates the need for recurring clinic visits for administration, a barrier in rural areas where endocrinology clinics may be hours away.

Clinical Efficacy: Do They Work the Same?

The Testosterone Trials (TTrials), published in the New England Journal of Medicine in 2016, enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL and symptoms of hypogonadism [1]. Participants were randomized to testosterone gel (AndroGel 1%) or placebo for 12 months. The trial demonstrated statistically significant improvements in sexual function (P<0.001), physical function as measured by the 6-minute walk test (P=0.03), and vitality scores.

The TTrials used topical gel, not injectable enanthate. No large-scale randomized controlled trial has directly compared testosterone enanthate injections to testosterone gel head-to-head for clinical outcomes. Pharmacokinetic studies, however, confirm that both formulations raise serum testosterone into the eugonadal range of 300 to 1,000 ng/dL [5].

A key pharmacokinetic difference: injectable testosterone enanthate produces a peak-and-trough pattern. Serum testosterone spikes 48 to 72 hours after injection and declines over the following 7 to 14 days. Some men report mood fluctuations or energy dips near trough. Splitting the dose to weekly or twice-weekly injections flattens the curve. Testosterone gel produces more stable day-to-day serum levels, which the Endocrine Society guideline lists as a potential advantage for men sensitive to hormonal fluctuations [2].

Dr. Shalender Bhasin, principal investigator of the TTrials and professor at Harvard Medical School, stated in the NEJM publication: "Testosterone treatment increased serum testosterone levels to the mid-normal range for young men and was associated with significant improvements in sexual function and activity" [1]. The finding applied to gel-treated subjects, but subsequent meta-analyses have found no consistent efficacy difference between injectable and topical testosterone for symptom resolution.

A 2019 systematic review in the Journal of Clinical Endocrinology & Metabolism (JCEM) pooled data from 30 RCTs (N=1,549) and found that both intramuscular and transdermal testosterone improved sexual function, mood, and body composition with similar effect sizes [6]. The authors noted: "Route of administration did not significantly modify the treatment effect on any primary outcome."

Safety and Monitoring Differences

Both formulations carry the same FDA class-wide boxed warning regarding cardiovascular risk. The TRAVERSE trial (N=5,246), published in the NEJM in 2023, found that testosterone gel did not increase the incidence of major adverse cardiovascular events compared to placebo in men aged 45 to 80 with hypogonadism and pre-existing or high risk of cardiovascular disease (hazard ratio 0.96; 95% CI, 0.78 to 1.17) [7]. This provided reassurance, but the FDA has not removed the boxed warning.

Polycythemia (hematocrit above 54%) is the most common laboratory adverse effect of testosterone therapy. Injectable formulations may produce slightly higher peak hematocrit levels than gels due to the supraphysiologic peak concentrations post-injection. The Endocrine Society recommends checking hematocrit at 3 to 6 months after initiation and annually thereafter for both formulations [2]. If hematocrit exceeds 54%, options include dose reduction, switching from injection to gel, or therapeutic phlebotomy.

Skin transfer is a safety concern unique to topical testosterone. The FDA requires AndroGel labeling to include warnings about secondary exposure, particularly to women and children, which can cause virilization [8]. Men using testosterone gel must apply it to clean, dry skin on the shoulders or upper arms, cover the area with clothing after drying, and wash hands immediately. Intimate skin-to-skin contact should be avoided until the application site has been washed. Injections eliminate this risk entirely, which makes them the preferred formulation for men with young children at home or female partners who are pregnant or may become pregnant.

Injection-site reactions (pain, swelling, nodules) occur in a minority of patients using intramuscular testosterone. Subcutaneous injection with a 25- to 27-gauge needle has gained popularity as an off-label alternative that reduces discomfort. A 2017 study in Translational Andrology and Urology found subcutaneous testosterone injections produced comparable serum levels with fewer injection-site complaints [9].

Who Should Choose Which Formulation

The decision is not purely clinical. It is also financial, logistical, and personal. Here is a practical framework.

Choose testosterone enanthate injections if:

• You are paying cash or have a high-deductible plan
• You are comfortable with self-injection (or willing to learn)
• You have young children or a partner at risk of secondary testosterone transfer
• You want the lowest possible monthly cost
• You prefer less frequent dosing (weekly or biweekly vs. daily)

Choose testosterone gel (AndroGel or generic) if:

• You have insurance that covers gel with a low copay
• You have a strong needle aversion that training cannot overcome
• You experience significant mood or energy swings on injectable TRT despite dose splitting
• You prefer a daily routine over an injection schedule
• You do not live with individuals at risk for secondary transfer, or you can reliably prevent contact

The American Urological Association (AUA) and the Endocrine Society both endorse shared decision-making for TRT formulation selection [2][10]. Neither organization ranks one formulation above another in its treatment algorithm. The best formulation is the one the patient will use consistently, because adherence determines outcomes.

Switching Between Formulations

Switching from testosterone enanthate to gel or vice versa is common and clinically straightforward. No washout period is required. When moving from injectable to gel, most clinicians start the gel on the day the next injection would have been due. When switching from gel to injectable, the first injection is typically given the day after stopping gel application.

Serum testosterone should be rechecked 4 to 6 weeks after any formulation change to confirm adequate levels. The target trough for injections (measured just before the next dose) is 400 to 700 ng/dL per Endocrine Society guidance [2]. For gels, levels are typically drawn 2 to 8 hours after application.

Dose equivalence is approximate, not exact. A man on 100 mg weekly of testosterone enanthate does not map neatly to a specific number of gel pump actuations. Most clinicians start gel at the manufacturer's recommended initial dose (40.5 mg daily for AndroGel 1.62%, or 50 mg daily for generic testosterone gel 1%) and titrate based on follow-up labs at 4 to 6 weeks.

The Generic Gel Middle Ground

Men who want topical convenience without the brand-name price tag should ask their prescriber to write for generic testosterone gel 1%. Priced at $80 to $150 per month, it sits between injectable and brand AndroGel in cost. Generic gel is available in packets (50 mg each) or pump bottles and is AB-rated as bioequivalent to original AndroGel 1% [8].

The 1% and 1.62% concentrations are not interchangeable. AndroGel 1.62% delivers more testosterone per gram of gel and uses a different application area (front and inner thighs for 1.62% vs. shoulders/upper arms for 1%). Prescribers must specify the concentration, and pharmacists cannot substitute one for the other.

For patients whose insurance formulary covers generic gel at Tier 1 or Tier 2, the monthly copay may approach injectable pricing, making the gel a reasonable option on both clinical and financial grounds.